Cargando…

A metabolic profile of polyamines in parkinson disease: A promising biomarker

OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiki, Shinji, Sasazawa, Yukiko, Fujimaki, Motoki, Kamagata, Koji, Kaga, Naoko, Taka, Hikari, Li, Yuanzhe, Souma, Sanae, Hatano, Taku, Imamichi, Yoko, Furuya, Norihiko, Mori, Akio, Oji, Yutaka, Ueno, Shin‐Ichi, Nojiri, Shuko, Miura, Yoshiki, Ueno, Takashi, Funayama, Manabu, Aoki, Shigeki, Hattori, Nobutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772170/
https://www.ncbi.nlm.nih.gov/pubmed/31155745
http://dx.doi.org/10.1002/ana.25516
_version_ 1783455852921880576
author Saiki, Shinji
Sasazawa, Yukiko
Fujimaki, Motoki
Kamagata, Koji
Kaga, Naoko
Taka, Hikari
Li, Yuanzhe
Souma, Sanae
Hatano, Taku
Imamichi, Yoko
Furuya, Norihiko
Mori, Akio
Oji, Yutaka
Ueno, Shin‐Ichi
Nojiri, Shuko
Miura, Yoshiki
Ueno, Takashi
Funayama, Manabu
Aoki, Shigeki
Hattori, Nobutaka
author_facet Saiki, Shinji
Sasazawa, Yukiko
Fujimaki, Motoki
Kamagata, Koji
Kaga, Naoko
Taka, Hikari
Li, Yuanzhe
Souma, Sanae
Hatano, Taku
Imamichi, Yoko
Furuya, Norihiko
Mori, Akio
Oji, Yutaka
Ueno, Shin‐Ichi
Nojiri, Shuko
Miura, Yoshiki
Ueno, Takashi
Funayama, Manabu
Aoki, Shigeki
Hattori, Nobutaka
author_sort Saiki, Shinji
collection PubMed
description OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. METHODS: Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. RESULTS: In Cohort A, N8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N1,N8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. INTERPRETATION: Spermine synthesis and N1,N8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263
format Online
Article
Text
id pubmed-6772170
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-67721702019-10-07 A metabolic profile of polyamines in parkinson disease: A promising biomarker Saiki, Shinji Sasazawa, Yukiko Fujimaki, Motoki Kamagata, Koji Kaga, Naoko Taka, Hikari Li, Yuanzhe Souma, Sanae Hatano, Taku Imamichi, Yoko Furuya, Norihiko Mori, Akio Oji, Yutaka Ueno, Shin‐Ichi Nojiri, Shuko Miura, Yoshiki Ueno, Takashi Funayama, Manabu Aoki, Shigeki Hattori, Nobutaka Ann Neurol Research Articles OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. METHODS: Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. RESULTS: In Cohort A, N8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N1,N8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. INTERPRETATION: Spermine synthesis and N1,N8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263 John Wiley & Sons, Inc. 2019-07-01 2019-08 /pmc/articles/PMC6772170/ /pubmed/31155745 http://dx.doi.org/10.1002/ana.25516 Text en © 2019 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Saiki, Shinji
Sasazawa, Yukiko
Fujimaki, Motoki
Kamagata, Koji
Kaga, Naoko
Taka, Hikari
Li, Yuanzhe
Souma, Sanae
Hatano, Taku
Imamichi, Yoko
Furuya, Norihiko
Mori, Akio
Oji, Yutaka
Ueno, Shin‐Ichi
Nojiri, Shuko
Miura, Yoshiki
Ueno, Takashi
Funayama, Manabu
Aoki, Shigeki
Hattori, Nobutaka
A metabolic profile of polyamines in parkinson disease: A promising biomarker
title A metabolic profile of polyamines in parkinson disease: A promising biomarker
title_full A metabolic profile of polyamines in parkinson disease: A promising biomarker
title_fullStr A metabolic profile of polyamines in parkinson disease: A promising biomarker
title_full_unstemmed A metabolic profile of polyamines in parkinson disease: A promising biomarker
title_short A metabolic profile of polyamines in parkinson disease: A promising biomarker
title_sort metabolic profile of polyamines in parkinson disease: a promising biomarker
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772170/
https://www.ncbi.nlm.nih.gov/pubmed/31155745
http://dx.doi.org/10.1002/ana.25516
work_keys_str_mv AT saikishinji ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT sasazawayukiko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT fujimakimotoki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT kamagatakoji ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT kaganaoko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT takahikari ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT liyuanzhe ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT soumasanae ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT hatanotaku ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT imamichiyoko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT furuyanorihiko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT moriakio ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT ojiyutaka ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT uenoshinichi ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT nojirishuko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT miurayoshiki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT uenotakashi ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT funayamamanabu ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT aokishigeki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT hattorinobutaka ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT saikishinji metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT sasazawayukiko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT fujimakimotoki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT kamagatakoji metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT kaganaoko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT takahikari metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT liyuanzhe metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT soumasanae metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT hatanotaku metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT imamichiyoko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT furuyanorihiko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT moriakio metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT ojiyutaka metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT uenoshinichi metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT nojirishuko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT miurayoshiki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT uenotakashi metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT funayamamanabu metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT aokishigeki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker
AT hattorinobutaka metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker